Trials / Completed
CompletedNCT05600114
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 239 (actual)
- Sponsor
- EmpowerPharm Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cannabidiol oral solution | CBD 150 mg BID |
| DRUG | Cannabidiol oral solution | CBD 300 mg BID |
| DRUG | Placebo | Placebo BID |
Timeline
- Start date
- 2022-10-27
- Primary completion
- 2023-12-13
- Completion
- 2023-12-13
- First posted
- 2022-10-31
- Last updated
- 2024-11-21
Locations
17 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05600114. Inclusion in this directory is not an endorsement.